0000000000263604

AUTHOR

Chim C. Lang

showing 4 related works from this author

Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF

2020

Aims: \ud This retrospective analysis sought to identify markers that might distinguish between acute heart failure (HF) and worsening HF in chronic outpatients.\ud \ud Methods and Results: \ud The BIOSTAT‐CHF index cohort included 2516 patients with new or worsening HF symptoms: 1694 enrolled as inpatients (acute HF) and 822 as outpatients (worsening HF in chronic outpatients). A validation cohort included 935 inpatients and 803 outpatients. Multivariable models were developed in the index cohort using clinical characteristics, routine laboratory values, and proteomics data to examine which factors predict adverse outcomes in both conditions and to determine which factors differ between ac…

medicine.medical_specialtyAdverse outcomesacute heart failure treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemacute heart failure diagnosisInternal medicineOutpatientsDiagnosismedicineRetrospective analysisHumansAcute heart failure; acute heart failure diagnosis; acute heart failure treatmentRetrospective StudiesHeart Failurebusiness.industryTreatment developmentRoutine laboratoryAcute heart failurePrognosismedicine.diseaseR1[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHospitalizationTreatmentHeart failureChronic DiseaseCohortBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessCarbohydrate antigen
researchProduct

Clinical Role of CA125 in Worsening Heart Failure

2020

Abstract Objectives The aim of this study was to evaluate the association between antigen carbohydrate 125 (CA125) and the risk of 1-year clinical outcomes in patients with worsening heart failure (HF). Background CA125 is a widely available biomarker that is up-regulated in patients with acute HF and has been postulated as a useful marker of congestion and risk stratification. Methods In a large multicenter cohort of patients with worsening HF, either in-hospital or in the outpatient setting, the independent associations between CA125 and 1-year death and the composite of death/HF readmission (adjusted for outcome-specific prognostic risk score [BIOSTAT risk score]) were determined by usin…

medicine.medical_specialtyFramingham Risk Scoreendocrine system diseasesbusiness.industrymedicine.drug_class030204 cardiovascular system & hematologymedicine.diseaseTailored treatmentfemale genital diseases and pregnancy complications03 medical and health sciences0302 clinical medicineIncreased riskHeart failureInternal medicineCohortmedicineNatriuretic peptideBiomarker (medicine)In patient030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessJACC: Heart Failure
researchProduct

Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure

2022

Introduction and objectives: Carbohydrate antigen 125 (CA125) has been shown to be useful for risk stratification in patients admitted with acute heart failure (AHF). We sought to determine a CA125 cutpoint for identifying patients at low risk of 1-month death or the composite of death/HF readmission following admission for AHF.Methods: The derivation cohort included 3231 consecutive patients with AHF. CA125 cutoff values with 90% negative predictive value (NPV) and sensitivity up to 85% were identified. The adequacy of these cutpoints and the risk of 1-month death/HF readmission was then tested using the Royston-Parmar method. The best cutpoint was selected and externally validated in a co…

medicine.medical_specialtyOptimal cutoffAntígeno carbohidrato 125MONOCLONAL-ANTIBODYendocrine system diseasesCarbohydratesAftercareInsuficiencia cardiaca aguda030204 cardiovascular system & hematologyWorsening Heart FailureCA12503 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCutoffIn patientOutcomeHeart FailureNATRIURETIC PEPTIDEbusiness.industryMORTALITYPronósticoGeneral MedicineCongestiónPrognosismedicine.diseasePredictive valuePatient Dischargefemale genital diseases and pregnancy complicationsAntígeno carbohidrato 125; CA125; Carbohydrate antigen 125; Congestion; Congestión; Insuficiencia cardiaca aguda; Outcome; Pronóstico; Worsening Heart Failure; Acute Disease; CA-125 Antigen; Carbohydrates; Humans; Patient Discharge; Prognosis; Aftercare; Heart FailureCarbohydrate antigen 125CA-125 AntigenHeart failureAcute DiseaseCohortRisk stratificationCongestionbusinessCarbohydrate antigenRevista Española de Cardiología (English Edition)
researchProduct

Punto de corte óptimo del antígeno carbohidrato 125 para la identificación de pacientes con bajo riesgo tras un ingreso por insuficiencia cardiaca ag…

2022

Resumen Introduccion y objetivos El antigeno carbohidrato 125 (CA125) se ha mostrado util para la estratificacion del riesgo de los pacientes ingresados por insuficiencia cardiaca aguda (ICA). Se intenta determinar un punto de corte para identificar a los pacientes con bajo riesgo de muerte y muerte/reingreso por insuficiencia cardiaca 1 mes tras el ingreso por ICA. Metodos La cohorte de derivacion incluyo a 3.231 pacientes con ICA consecutivos. Se identificaron valores de corte de CA125 con un valor predictivo negativo (VPN) del 90% y una sensibilidad de hasta el 85%. La idoneidad de estos puntos de corte y el riesgo de muerte/reingreso al mes se evaluaron mediante el metodo de Royston-Par…

03 medical and health sciences0302 clinical medicinebusiness.industryMedicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct